Systemic Sclerosis and Kaposi's Sarcoma with Pulmonary Involvement: An Unexpected Association

2017 ◽  
Vol 53 (3) ◽  
pp. 165-166
Author(s):  
Francisca Aguiar ◽  
David Araújo ◽  
Iva Brito
Keyword(s):  
Systemic Sclerosis ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Pulmonary Involvement

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

1998 ◽  
Vol 16 (3) ◽  
pp. 1112-1121 ◽  
Author(s):  
L Welles ◽  
M W Saville ◽  
J Lietzau ◽  
J M Pluda ◽  
K M Wyvill ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Kaposi's Sarcoma ◽  
Single Agent ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Pulmonary Involvement ◽  
Dose Titration ◽  
Treatment Schedule ◽  
Creatinine Concentration ◽  
Immunodeficiency Virus

PURPOSE To investigate the antitumor activity and safety of paclitaxel in patients with advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Twenty-nine patients with advanced HIV-associated KS were enrolled. The patients were overall quite immunosuppressed (median CD4 count, 15 cells/microL). Paclitaxel was initially administered at 135 mg/m2 over 3 hours every 3 weeks without filgrastim support; the dose was increased as tolerated to a maximum of 175 mg/m2. Patients who failed to respond or progressed could then receive filgrastim support or paclitaxel administered over 96 hours. RESULTS Of 28 assessable patients, 20 had major responses (18 partial responses [PRs], one clinical complete response [CR], and one CR), for a major response rate of 71.4% (95% confidence interval [CI], 51.3% to 86.8%). Each of the five patients with pulmonary KS responded, as did all four assessable patients who had previously received anthracycline therapy for KS. Of six patients who went on to receive a 96-hour infusion of paclitaxel, five had major responses. Neutropenia was the most frequent dose-limiting toxicity; possible novel toxicities included late fevers, late rash, and eosinophilia. Two patients developed an elevated creatinine concentration and one cardiomyopathy. CONCLUSION Paclitaxel has substantial activity against advanced HIV-associated KS as a single agent, even in patients with pulmonary involvement or who had previously received anthracyclines. Further research is needed to define the optimal treatment schedule and its role vis-a-vis the other available therapies for this disease.

Classic Kaposi's sarcoma with pulmonary involvement in an HIV-negative woman

1995 ◽  
Vol 20 (5) ◽  
pp. 410-412
Author(s):  
J. COLL ◽  
J. PEDRO-BOTET ◽  
J.O. PALLAS ◽  
A.M. GIMENEZ-ARNAU ◽  
C. BARRANCO
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Pulmonary Involvement ◽  
Negative Woman ◽  
Hiv Negative

Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy

2001 ◽  
Vol 19 (18) ◽  
pp. 3848-3851 ◽  
Author(s):  
Beata Holkova ◽  
Kenichi Takeshita ◽  
Debbie M. Cheng ◽  
Matthew Volm ◽  
Carolyn Wasserheit ◽  
...  
Keyword(s):  
New York ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Pulmonary Involvement ◽  
Risk Of Death ◽  
Chemotherapy Administration ◽  
Highly Active ◽  
Kaplan Meier

PURPOSE: Kaposi’s sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS. PATIENTS AND METHODS: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause. RESULTS: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69). CONCLUSION: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.

Kaposi's sarcoma localized to the penis

1970 ◽  
Vol 102 (4) ◽  
pp. 461-462 ◽  
Author(s):  
J. W. Cox
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma
Sign in / Sign up

Export Citation Format

Share Document